CENCORA DL-,01/ US03073E1055 /
5/15/2024 3:48:30 PM | Chg. -1.200 | Volume | Bid5:13:23 PM | Ask5:13:23 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
204.900EUR | -0.58% | 21 Turnover: 4,304.750 |
205.350Bid Size: 150 | 206.100Ask Size: 150 | 41.15 bill.EUR | - | - |
GlobeNewswire
5/13
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
5/9
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire
4/29
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...
GlobeNewswire
4/17
2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners
GlobeNewswire
3/22
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...
GlobeNewswire
3/18
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire
2/14
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire
1/23
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...
GlobeNewswire
12/22/2023
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...
GlobeNewswire
12/19/2023
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...
GlobeNewswire
11/27/2023
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...
GlobeNewswire
11/14/2023
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...
GlobeNewswire
11/1/2023
Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (IN...
GlobeNewswire
9/21/2023
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference